DYSPORT (abobotulinumtoxinA), is a FDA-approved (The U.S. Food and Drug Administration's (FDA) approval April 30, 2009); acetylcholine release inhibitor and a neuromuscular blocking agent. The approval includes two separate indications, the treatment of cervical dystonia in adults to reduce the severity of abnormal head position and neck pain, and the temporary improvement in the appearance of moderate to severe glabellar lines in adults younger than 65 years of age. Medicis will market DYSPORTT in the U.S. for the aesthetic indication (glabellar lines). Additionally, DYSPORTT is differentiated from other marketed botulinum toxin products with the unique established name abobotulinumtoxinA.

DYSPORTT was evaluated for the treatment of glabellar lines in robust clinical studies, which included approximately 2,900 patients at more than 80 clinical study sites.1 The active substance in DYSPORTT is a botulinum neurotoxin type A complex, which acts at the level of the neuromuscular junction in the targeted muscle. DYSPORTT is a neuromuscular blocking toxin which acts to block acetylcholine release at motor nerve ends and reduces muscular spasm.

Used in patient care in the United Kingdom since 1991, DYSPORTT has marketing authorizations in 76 countries for therapeutic use and in 27 countries for aesthetic use. Patient exposure is estimated to be above two million single treatment cycles, representing more than 600,000 patients year of treatment.

Medicis is the leading independent specialty pharmaceutical company in the United States focusing primarily on the treatment of dermatological and aesthetic conditions. In addition to DYSPORTT, Medicis also manufactures the brands RESTYLANE® (hyaluronic acid) and PERLANE® (hyaluronic acid). .